| Literature DB >> 27930691 |
José Inácio Salles1,2, Maria Eugenia Leite Duarte1, João Matheus Guimarães1, Lucas Rafael Lopes1,3, Jessica Vilarinho Cardoso3,4, Diego Pinheiro Aguiar1, João Olyntho Machado Neto5, Daniel Escorsim Machado3, Jamila Alessandra Perini1,3,4.
Abstract
The aim of the study was to investigate whether genetic variants in VEGF and KDR genes can be correlated with susceptibility of tendinopathy in volleyball athletes. This study was conducted at the Brazilian Volleyball Federation, and comprised 179 volleyball athletes: 88 had a confirmed diagnosis of tendinopathy (cases), whereas 91 had no evidence of the disease (controls). The VEGF (-2578C>A, -460T>C and +936C>T) and KDR (-604C>T, 1192G>A and 1719T>A) polymorphisms were determined by TaqMan real-time polymerase chain reaction. The odds ratio (OR) with their 95% confidence intervals (CI) were calculated using an unconditional logistic regression model. The evaluation of demographic and clinical characteristics revealed the athlete age (P < 0.001), years of practice in volleyball (P < 0.001) and presence of pain (P = 0.001) were risk factors for tendinopathy. KDR 1192 GA and GA + AA genotypes were associated with lower risk of tendinopathy (OR: 0.41, 95% CI: 0.19-0.88 and OR: 0.47, 95% CI: 0.23-0.98, respectively). The KDR (-604C>T, 1192G>A and 1719T>A) haplotypes CGA and CAT were associated with decreased tendinopathy risk (OR: 0.46, 95% CI: 0.21-0.99 and OR: 0.23, 95% CI: 0.07-0.76, respectively). With regards to pain, traumatic lesion and away from training due to injury, VEGF and KDR polymorphisms were not associated with clinical symptoms complaints. The present results provide evidence that the KDR polymorphisms were associated with development of tendinopathy, and can contribute to identify new therapeutic targets or personalized training programs to avoid tendinopathy development in athletes.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27930691 PMCID: PMC5145183 DOI: 10.1371/journal.pone.0167717
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characterization of KDR polymorphisms, probes and primers sequences for genotyping by TaqMan real time PCR.
| Identified SNP | TaqMan assays | Region | Probe [SNP] | Primer |
|---|---|---|---|---|
| rs2071559 | C__15869271_10 | PR | Forward: | |
| Reverse: | ||||
| rs2305948 | C__22271999_20 | Exon 7 | Forward: | |
| Reverse:5'- | ||||
| rs1870377 | C__11895315_20 | Exon 11 | Forward: | |
| Reverse: |
PR is Promoter Region.
Demographic and clinical characteristics of the volleyball athletes.
| Variables | Controls (n = 91) | Tendinopathy (n = 88) | |
|---|---|---|---|
| Age (years) | N (%) | ||
| Sub 18 | 46 (50.5) | 14 (15.9) | < 0.001 |
| Sub 23 | 29 (31.9) | 33 (37.5) | |
| Adult | 16 (17.6) | 41 (46.6) | |
| Years of practice in volleyball | |||
| 0–5 | 40 (44.0) | 17 (19.3) | < 0.001 |
| 6–10 | 32 (35.2) | 39 (44.3) | |
| 11–15 | 12 (13.2) | 31 (35.2) | |
| > 15 | 7 (7.7) | 1 (1.1) | |
| Gender of the athletes | |||
| Female | 52 (57.1) | 29 (33.0) | 0.001 |
| Male | 39 (42.9) | 59 (67.0) | |
| Declared preference | |||
| Right | 88 (96.7) | 86 (97.7) | 0.68 |
| Left | 3 (3.3) | 3 (2.3) | |
| Function | |||
| Spiker | 69 (75.8) | 71 (80.7) | 0.73 |
| Setter | 16 (17.6) | 12 (13.6) | |
| Libero | 6 (6.6) | 5 (5.7) | |
| Pain in any joint | |||
| No | 31 (34.1) | 12 (13.6) | 0.001 |
| Yes | 60 (65.9) | 76 (86.4) | |
| Traumatic lesion | |||
| No | 60 (65.9) | 58 (65.9) | 0.99 |
| Yes | 31 (34.1) | 30 (34.1) | |
| Away from training due to injury | |||
| No | 64 (70.3) | 49 (55.7) | 0.04 |
| Yes | 27 (29.7) | 39 (44.3) | |
aChi-Square Test or Fisher’s exact test.
Fig 1Allelic frequency of VEGF and KDR polymorphisms in tendinopathy cases and controls.
Fig 2Genotypic distribution of VEGF and KDR polymorphisms in volleyball athletes.
Association analyses of the KDR 1192G>A polymorphism in tendinopathy cases compared with athletes without disease.
| Controls (n = 91) | Tendinopathy (n = 88) | OR (95% CI) | ||
|---|---|---|---|---|
| N (%) | ||||
| GG | 59 (64.8) | 67 (76.1) | 1 | |
| GA | 30 (33.0) | 18 (20.5) | 0.02 | 0.41 (0.19–0.88) |
| AA | 2 (2.2) | 3 (3.4) | 0.63 | 1.61 (0.23–11.5) |
| GA + AA | 32 (35.2) | 21 (23.9) | 0.04 | 0.47 (0.23–0.98) |
OR, odds ratio; CI, confidence interval
aChi-Square Test or Fisher’s exact test
bAdjusted by age, years of practice in volleyball, gender and pain
cReference group.
Haplotype distributions of VEGF and KDR in volleyball athletes and their association with tendinopathy risk.
| Haplotypes | Controls (n = 182) | Tendinopathy (n = 176) | OR (95% CI) | |
|---|---|---|---|---|
| N (%) | ||||
| CTC | 109 (59.9) | 101 (57.4) | 1c | |
| CTT | 1 (0.6) | 2 (1.1) | 0.93 | 1.06 (0.28–3.97) |
| CCC | 5 (2.7) | 8 (4.5) | 0.53 | 1.49 (0.44–5.07) |
| CCT | 5 (2.7) | 6 (3.4) | 0.72 | 1.58 (0.13–19.5) |
| ACC | 42 (23.1) | 45 (25.6) | 0.62 | 1.14 (0.67–1.94) |
| ACT | 17 (9.3) | 12 (6.8) | 0.38 | 0.68 (0.29–1.61) |
| ATT | 2 (1.1) | 1 (0.6) | 0.88 | 0.82 (0.07–10.1) |
| ATC | 1 (0.6) | 1 (0.6) | 0.66 | 1.86 (0.11–31.0) |
| N (%) | ||||
| CGT | 48 (26.4) | 50 (28.4) | 1 | |
| CGA | 31 (17.0) | 19 (10.8) | 0.49 | 0.46 (0.21–0.99) |
| CAT | 15 (8.2) | 5 (2.9) | 0.02 | 0.23 (0.07–0.76) |
| CAA | 11 (6.1) | 15 (8.5) | 0.94 | 1.04 (0.42–2.59) |
| TGT | 57 (31.3) | 65 (37.0) | 0.63 | 1.10 (0.64–1.86) |
| TGA | 12 (6.6) | 18 (10.2) | 0.79 | 1.13 (0.46–2.78) |
| TAT | 2 (1.1) | 2 (1.1) | 0.58 | 0.53 (0.06–5.04) |
| TCA | 6 (3.3) | 2 (1.1) | 0.18 | 0.31 (0.06–1.71) |
Number (%); OR, odds ratio; CI, confidence interval
aChi-Square Test or Fisher’s exact test
bAdjusted by age, years of practice in volleyball, gender and pain
cReference Group